Characterization of pancreatic ductal cells in human islet preparations.
Substantial amounts of nonendocrine cells are implanted as part of human islet grafts, and a possible influence of nonendocrine cells on clinical islet transplantation outcome has been postulated. There are currently no product release criteria specific for nonendocrine cells due to lack of available methods. The aims of this study were to develop a method for the evaluation of pancreatic ductal cells (PDCs) for clinical islet transplantation and to characterize them regarding phenotype, viability, and function. We assessed 161 human islet preparations using laser scanning cytometry (LSC/iCys) for phenotypic analysis of nonendocrine cells and flow cytometry (FACS) for PDC viability. PDC and beta-cells obtained from different density fractions during the islet cell purification were compared in terms of viability. Furthermore, we examined PDC ability to produce proinflammatory cytokines/chemokines, vascular endothelial growth factor (VEGF) and tissue factor (TF) relevant to islet graft outcome. Phenotypic analysis by LSC/iCys indicated that single staining for CK19 or CA19-9 was not enough for identifying PDCs, and that double staining for amylase and CK19 or CA19-9 allowed for quantitative evaluation of acinar cells and PDC content in human islet preparation. PDC showed a significantly higher viability than beta-cells (PDC vs beta-cell: 75.5+/-13.9 and 62.7+/-18.7%; P<0.0001). Although beta-cell viability was independent of its density, that of PDCs was higher as the density from which they were recovered increased. There was no correlation between PDCs and beta-cell viability (R(2)=0.0078). PDCs sorted from high-density fractions produced significantly higher amounts of proinflammatory mediators and VEGF, but not TF. We conclude that PDCs isolated from different fractions had different viability and functions. The precise characterization and assessment of these cells in addition to beta-cells in human islet cell products may be of assistance in understanding their contribution to islet engraftment and in developing strategies to enhance islet graft function.
Ichii
Hirohito
H
Cell Transplant Center, Diabetes Research Institute, University of Miami Leonard M. Miller School of Medicine, Miami, FL 33136, USA. hichii@med.miami.edu
Miki
Atsushi
A
Yamamoto
Toshiyuki
T
Molano
Ruth D
RD
Barker
Scott
S
Mita
Atsuyoshi
A
Rodriguez-Diaz
Rayner
R
Klein
Dagmar
D
Pastori
Ricardo
R
Alejandro
Rodolfo
R
Inverardi
Luca
L
Pileggi
Antonello
A
Ricordi
Camillo
C
D000818:Animals; D018395:CA-19-9 Antigen; D003921:Diabetes Mellitus, Experimental; D006801:Humans; D050417:Insulin-Secreting Cells / Q000145:classification / Q000166:cytology*; D007515:Islets of Langerhans / Q000166:cytology; D016381:Islets of Langerhans Transplantation; D053539:Keratin-19; D047569:Laser Scanning Cytometry; D051379:Mice; D008819:Mice, Nude; D010183:Pancreatic Ducts / Q000166:cytology*; D010641:Phenotype
D018395:CA-19-9 Antigen; D053539:Keratin-19
Science. 2003 Nov 14;302(5648):1223-7
14615542
Diabetes. 2008 Aug;57(8):2128-36
18492788
Diabetes. 2007 Jul;56(7):1802-9
17473224
Biochem Biophys Res Commun. 2004 Jul 16;320(1):27-33
15207697
Am J Transplant. 2007 Jan;7(1):38-47
17227556
Am J Transplant. 2007 Mar;7(3):707-13
17229069
J Clin Invest. 2003 Mar;111(6):843-50
12639990
Am J Transplant. 2006 Nov;6(11):2601-11
16981910
N Engl J Med. 2000 Jul 27;343(4):230-8
10911004
Am J Transplant. 2004 Mar;4(3):390-401
14961992
Am J Transplant. 2005 Jan;5(1):21-30
15636608
Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8078-83
12048252
Diabetes. 1999 Jan;48(1):29-33
9892219
Curr Opin Immunol. 1997 Jun;9(3):330-7
9203418
Transplantation. 1988 Sep;46(3):457-60
3047936
Diabetes. 2000 Feb;49(2):157-62
10868930
Lancet. 2002 Dec 21-28;360(9350):2039-45
12504401
Am J Transplant. 2006 Sep;6(9):2060-8
16827790
Ann Surg. 2003 Jun;237(6):741-9; discussion 749-50
12796569
J Leukoc Biol. 2000 Jan;67(1):2-17
10647992
Diabetes. 2006 Sep;55(9):2437-45
16936191
Transplantation. 1988 Apr;45(4):827-30
2451869
Science. 2001 May 18;292(5520):1389-94
11326082
Endocrinology. 2003 Jul;144(7):3037-45
12810560
Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):7999-8004
10884429
Diabetes. 2006 Sep;55(9):2429-36
16936190
Am J Transplant. 2007 Apr;7(4):1010-20
17391141
Cell Transplant. 2006;15(8-9):745-58
17269445
N Engl J Med. 2006 Sep 28;355(13):1318-30
17005949
Nat Med. 2000 Mar;6(3):278-82
10700229
Diabetes Metab Res Rev. 2004 Jan-Feb;20(1):13-27
14737742
Diabetes. 2005 Jun;54(6):1755-62
15919797
Diabetes. 1988 Apr;37(4):413-20
3288530
Diabetes. 2005 Jul;54(7):2060-9
15983207
J Clin Endocrinol Metab. 2004 Nov;89(11):5724-8
15531535
Diabetologia. 2006 Oct;49(10):2341-9
16896936
Diabetes. 2004 Dec;53(12):3107-14
15561940
Diabetologia. 2005 Feb;48(2):268-76
15690148
Diabetes. 2004 Jun;53(6):1407-11
15161741
Am J Transplant. 2007 Apr;7(4):1021-6
17391142
Am J Transplant. 2006 Oct;6(10):2483-7
16869808
J Endocrinol. 2005 Jun;185(3):445-55
15930171
J Endocrinol. 1999 Jun;161(3):357-64
10333538
Annu Rev Immunol. 1998;16:111-35
9597126
Am J Transplant. 2005 Jul;5(7):1635-45
15943621
Am J Transplant. 2005 Aug;5(8):2037-46
15996257
Diabetes. 2002 Jan;51(1):55-65
11756323
Cell Transplant. 2001 Jan-Feb;10(1):109-21
11294467
Diabetologia. 1998 Jun;41(6):629-33
9662042
Diabetes. 2003 Aug;52(8):2007-15
12882917